SecBot SecBot
SECBOTREPLAY Home › Report › REGN

REGN · Regeneron filed an 8-K pre-announcing an expected ~$127M pre-tax…

REGENERON PHARMACEUTICALS, INC. · 8-K filed Jul 6, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Jul 6, 2026 at 07:00 ET

Regeneron filed an 8-K pre-announcing an expected ~$127M pre-tax acquired IPR&D charge for Q2 2026, which will reduce GAAP and non-GAAP EPS by approximately $1.00 per diluted share. This is a non-cash charge tied to collaboration and licensing payments, not an operational deterioration, but it signals ongoing deal activity and will create a one-time headwind to reported Q2 earnings.

  • Regeneron expects a ~$127M pre-tax acquired IPR&D charge in Q2 2026 from collaboration and licensing up-front/opt-in payments.
  • The charge is expected to reduce GAAP and non-GAAP EPS by approximately $1.00 per diluted share in Q2 2026.
  • The charge is non-cash and deal-related, not an operational deterioration, Regeneron does not forecast such charges due to their uncertain timing.
  • Q2 2026 results are not yet finalized and remain subject to closing procedures.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access